Printer Friendly

BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON TAXOL

 NEW YORK, Nov. 16 ~PRNewswire~ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration's Oncologic Drug Advisory Committee has recommended that Taxol (R) (paclitaxel) be approved by FDA for use in treating patients with cancer of the ovary who have failed standard therapy.
 The New Drug Application for Taxol was submitted to the FDA on July 22, 1992, 18 months after Bristol-Myers Squibb entered into the Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. The original objective, as specified by the CRADA, was to file an NDA within four years.
 Bristol-Myers Squibb is a diversified, research-based health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices.
 -0- 11~16~92
 ~CONTACT: Nancy L. Goldfarb of Bristol-Myers Squibb Company 212-546-5107~
 (BMY)


CO: Bristol-Myers Squibb Company ST: New York IN: MTC SU:

AH -- NY057 -- 1237 11~16~92 11:39 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 16, 1992
Words:152
Previous Article:HARRIS BANK'S MUTUAL FUND RATED TOP PERFORMING BANK FUND
Next Article:NATIONAL BENEVOLENT ASSOCIATION REVENUE BONDS RATED 'A-' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
BRISTOL-MYERS SQUIBB ISSUES STATEMENT ON TAXOL
BRISTOL-MYERS SQUIBB RESPONDS TO CONGRESSIONAL HEARINGS
BRISTOL-MYERS SQUIBB FILES CLAIMS AGAINST CANADIAN COMPANY FOR MISREPRESENTATION OF ANTICANCER PRODUCT
Bristol-Myers Squibb Acquires Novel Oncology Drug From Manitoba Cancer Treatment & Research Foundation
Bristol-Myers Squibb Announces Agreements with The National Institutes of Health
Bristol-Myers Squibb's Taxol(R) Receives Marketing Authorization In Japan For Advanced Ovarian Cancer
Bristol-Myers Squibb Taxol(R) Data Exclusivity in Europe Upheld by Dutch Court
Bristol-Myers Squibb & Phyton Agree to Commercialize Innovative Technology For Production of TAXOL(R)
Bristol-Myers Squibb & Phyton Agree to Commercialize Innovative Technology for Production of TAXOL(R)
Cytoclonal Isolates New Class of Late Taxol(R) Genes; Company Receives Paclitaxel (Taxol(R)) Payment.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters